Ryan M Kahn1, Sushmita Gordhandas1, Brandon Paul Maddy1, Becky Baltich Nelson2, Gulce Askin3, Paul J Christos3, Thomas A Caputo4, Eloise Chapman-Davis4, Kevin Holcomb4, Melissa K Frey4. 1. Department of Obstetrics and Gynecology, Weill Cornell Medical College, New York, New York. 2. Department of Information Technologies and Services, Weill Cornell Medical College, New York, New York. 3. Clinical and Translational Science Center, Department of Biostatistics and Epidemiology, Weill Cornell Medical College, New York, New York. 4. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Weill Cornell Medical College, New York, New York.
Abstract
BACKGROUND: Universal tumor testing for defective DNA mismatch repair (MMR) is recommended for all women diagnosed with endometrial cancer to identify those with underlying Lynch syndrome. However, the effectiveness of these screening methods in identifying individuals with Lynch syndrome across the population has not been well studied. The aim of this study was to evaluate outcomes of MMR immunohistochemistry (IHC), mutL homolog 1 (MLH1) methylation, and microsatellite instability (MSI) analysis among patients with endometrial cancer. METHODS: A complete systematic search of online databases (PubMed, EMBASE, MEDLINE, and the Cochrane Library) for 1990-2018 was performed. A DerSimonian-Laird random effects model meta-analysis was used to estimate the weighted prevalence of Lynch syndrome diagnoses. RESULTS: The comprehensive search produced 4400 publications. Twenty-nine peer-reviewed studies met the inclusion criteria. Patients with endometrial cancer (n = 6649) were identified, and 206 (3%) were confirmed to have Lynch syndrome through germline genetic testing after positive universal tumor molecular screening. Among 5917 patients who underwent tumor IHC, 28% had abnormal staining. Among 3140 patients who underwent MSI analysis, 31% had MSI. Among patients with endometrial cancer, the weighted prevalence of Lynch syndrome germline mutations was 15% (95% confidence interval [CI], 11%-18%) with deficient IHC staining and 19% (95% CI, 13%-26%) with a positive MSI analysis. Among 1159 patients who exhibited a loss of MLH1 staining, 143 (13.7%) were found to be MLH1 methylation-negative among those who underwent methylation testing, and 32 demonstrated a germline MLH1 mutation (2.8% of all absent MLH1 staining cases and 22.4% of all MLH1 methylation-negative cases). Forty-three percent of patients with endometrial cancer who were diagnosed with Lynch syndrome via tumor typing would have been missed by family history-based screening alone. CONCLUSIONS: Despite the widespread implementation of universal tumor testing in endometrial cancer, data regarding testing results remain limited. This study provides predictive values that will help practitioners to evaluate abnormal results in the context of Lynch syndrome and aid them in patient counseling.
BACKGROUND: Universal tumor testing for defective DNA mismatch repair (MMR) is recommended for all women diagnosed with endometrial cancer to identify those with underlying Lynch syndrome. However, the effectiveness of these screening methods in identifying individuals with Lynch syndrome across the population has not been well studied. The aim of this study was to evaluate outcomes of MMR immunohistochemistry (IHC), mutL homolog 1 (MLH1) methylation, and microsatellite instability (MSI) analysis among patients with endometrial cancer. METHODS: A complete systematic search of online databases (PubMed, EMBASE, MEDLINE, and the Cochrane Library) for 1990-2018 was performed. A DerSimonian-Laird random effects model meta-analysis was used to estimate the weighted prevalence of Lynch syndrome diagnoses. RESULTS: The comprehensive search produced 4400 publications. Twenty-nine peer-reviewed studies met the inclusion criteria. Patients with endometrial cancer (n = 6649) were identified, and 206 (3%) were confirmed to have Lynch syndrome through germline genetic testing after positive universal tumor molecular screening. Among 5917 patients who underwent tumor IHC, 28% had abnormal staining. Among 3140 patients who underwent MSI analysis, 31% had MSI. Among patients with endometrial cancer, the weighted prevalence of Lynch syndrome germline mutations was 15% (95% confidence interval [CI], 11%-18%) with deficient IHC staining and 19% (95% CI, 13%-26%) with a positive MSI analysis. Among 1159 patients who exhibited a loss of MLH1 staining, 143 (13.7%) were found to be MLH1 methylation-negative among those who underwent methylation testing, and 32 demonstrated a germline MLH1 mutation (2.8% of all absent MLH1 staining cases and 22.4% of all MLH1 methylation-negative cases). Forty-three percent of patients with endometrial cancer who were diagnosed with Lynch syndrome via tumor typing would have been missed by family history-based screening alone. CONCLUSIONS: Despite the widespread implementation of universal tumor testing in endometrial cancer, data regarding testing results remain limited. This study provides predictive values that will help practitioners to evaluate abnormal results in the context of Lynch syndrome and aid them in patient counseling.
Authors: Jennifer G Haag; Rebecca J Wolsky; Marisa R Moroney; Jamie Sheren; Jeanelle Sheeder; Benjamin G Bitler; Bradley R Corr Journal: Int J Gynecol Pathol Date: 2022-03-14 Impact factor: 3.326
Authors: Richard Gallon; Peter Gawthorpe; Rachel L Phelps; Christine Hayes; Gillian M Borthwick; Mauro Santibanez-Koref; Michael S Jackson; John Burn Journal: Cancers (Basel) Date: 2021-01-22 Impact factor: 6.639
Authors: Vanessa F Bonazzi; Olga Kondrashova; Deborah Smith; Katia Nones; Asmerom T Sengal; Robert Ju; Leisl M Packer; Lambros T Koufariotis; Stephen H Kazakoff; Aimee L Davidson; Priya Ramarao-Milne; Vanessa Lakis; Felicity Newell; Rebecca Rogers; Claire Davies; James Nicklin; Andrea Garrett; Naven Chetty; Lewis Perrin; John V Pearson; Ann-Marie Patch; Nicola Waddell; Pamela M Pollock Journal: Genome Med Date: 2022-01-10 Impact factor: 11.117
Authors: April Morrow; Katherine M Tucker; Tim J Shaw; Bonny Parkinson; Charles Abraham; Luke Wolfenden; Natalie Taylor Journal: BMJ Open Date: 2020-06-15 Impact factor: 2.692